Application 203797
- Type
- NDA
- Sponsor
- HOSPIRA INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DAPTOMYCIN | DAPTOMYCIN | POWDER;INTRAVENOUS | 350MG/VIAL | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| daptomycin | DAPTOMYCIN | Slate Run Pharmaceuticals, LLC | 3890474a-4425-43b3-97d4-5370cc35c2f7 | 2022-10-01 | Warnings, Adverse reactions | daptomycin DAPTOMYCIN |
| Daptomycin | DAPTOMYCIN | Fresenius Kabi USA, LLC | a990141d-7b92-48a5-a41d-1254522e2aa1 | 2022-06-09 | Warnings, Adverse reactions | Daptomycin DAPTOMYCIN |
| daptomycin | DAPTOMYCIN | Sagent Pharmaceuticals | f4ad8613-f25e-4b82-9621-cc5ff9525d3e | 2022-05-17 | Warnings, Adverse reactions | daptomycin DAPTOMYCIN |
| Daptomycin | DAPTOMYCIN | Hikma Pharmaceuticals USA Inc. | 1a7c9f52-7b58-49e9-93d7-5a26a7d1ef09 | 2022-04-29 | Warnings, Adverse reactions | Daptomycin DAPTOMYCIN |
| DAPZURA RT | DAPTOMYCIN | Baxter Healthcare Corporation | cb1283e1-35b8-425c-b338-d9ac0c7161f8 | 2022-01-25 | Warnings, Adverse reactions | DAPTOMYCIN |
| Daptomycin | DAPTOMYCIN | Dr. Reddy's Laboratories Inc., | d750e28d-1353-4671-66a3-ea4e49e81e7b | 2021-10-04 | Warnings, Adverse reactions | Daptomycin DAPTOMYCIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.